Company Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States.
The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.
It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations.
In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor.
It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer.
The company was incorporated in 2014 and is headquartered in Hamilton, Canada.
| Country | Canada |
| Founded | 2014 |
| IPO Date | Jun 26, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Dr. John F. Valliant Ph.D. |
Contact Details
Address: 270 Longwood Road South Hamilton, A6 L8P 0A6 Ontario, Canada | |
| Phone | 289-799-0891 |
| Website | fusionpharma.com |
Stock Details
| Ticker Symbol | FUSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001805890 |
| CUSIP Number | 36118A100 |
| ISIN Number | CA36118A1003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. John F. Valliant Ph.D. | Founder, Chief Executive Officer and Director |
| John J. Crowley CPA | Chief Financial Officer and Compliance Officer |
| Dr. Eric Burak Ph.D. | Chief Technology Officer |
| Mohit Rawat | President and Chief Business Officer |
| Dr. Christopher Paul Leamon Ph.D. | Chief Scientific Officer |
| Amanda Cray | Senior Director of Investor Relations and Corporate Communications |
| Maria D. Stahl | Chief Legal Officer |
| Eric S. Hoffman Ph.D. | Senior Vice President of Business Development |
| Dr. Cara Ferreira Ph.D. | Chief of Staff |
| Dr. Joanne Schindler | Executive Vice President of Medical Director and Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | DEFM14A | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | 8-K | Current Report |
| Apr 12, 2024 | 8-K/A | [Amend] Current report |
| Apr 12, 2024 | 10-K/A | [Amend] Annual report |
| Apr 10, 2024 | PREM14A | Filing |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 25, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Mar 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |